ArticlePloS one2025
The validation of the CTS-6 Evaluation Tool for diagnosing carpal tunnel syndrome (CTS) in Thai wheelchair users.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThe CTS-6 Evaluation Tool is a clinical diagnostic tool for carpal tunnel syndrome. It was originally developed using data from non-disabled individuals and has never been validated in different population. This study aimed to validate CTS-6's diagnostic performance at a cutoff score of 12 in a new population of wheelchair users.
methodsThe participants were 54 Thai wheelchair users from a university hospital's neuropathy registry. Those with a history of nerve injury, fracture, neuropathy, or pregnancy were excluded from the study. All underwent clinical exam, CTS-6, and electrodiagnosis (blinded evaluator). Carpal tunnel syndrome was diagnosed based on clinical symptoms and electrodiagnostic criteria.
resultsOf 54 participants, 13 were female (24.1%) with an average age of 46.9 (SD 12.2) years, and 18 (33.3%) participants had carpal tunnel syndrome. Duration of disability (years) was significantly longer in cases; median 24 (Q1 19.0, Q3 28.9), p < 0.001. Discriminative performance: Area under the receiver operating curve 0.935 (95%CI:0.891-0.978). At the 12 cutoff point, the sensitivity was 43.8% (95%CI:26.4-62.3%) and the specificity was 100.0% (95%CI:94.8-100.0%). A lower cutoff point showed increased sensitivity and specificity. Symptomatic subgroup analysis showed similar diagnostic performances.
conclusionThe CTS-6 Evaluation Tool is a simple clinical diagnostic tool that does not require sophisticated investigation. The CTS-6's discriminative ability remains strong. The diagnostic performance at a cutoff score of 12 showed moderate sensitivity and high specificity. Applying a cutoff score of 12 could help rule in the diagnosis where access to electrodiagnosis is limited. A lower cutoff score that is 7.5 could be applied as a screening test to rule out the diagnosis, as it provides moderately higher sensitivity at the cost of increased false positives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.